Novo Nordisk (NYSE:NVO) is exploring semaglutide as a potential treatment for alcohol use disorder, expanding beyond its current uses in diabetes and obesity. The company has also begun Phase 1 trials ...

Ozempic oral pill will be produced entirely in the US and distributed through more than 70,000 pharmacies in the US.

Quick Read CNBC’s Fast Money panel argues Novo Nordisk (NVO) now offers better value than Eli Lilly (LLY) after NVO’s 68% ...

With the recent launch of Novo Nordisk’s Wegovy pill opening the oral GLP-1 market for obesity, the company has now unveiled ...

Novo Nordisk A/S upgraded to Hold as FDA tightens compounded GLP-1s;Hims & Hers Health, Inc. stays Buy. Click for this NVO ...

The pharmaceutical industry has rarely seen a stock rise as spectacularly as Novo Nordisk (NVO 0.69%) did during the GLP-1 ...

The Food and Drug Administration proposed excluding Novo Nordisk and Eli Lilly's weight-loss drugs from a key compounding ...

Jan 12 (Reuters) - Novo Nordisk ‌CEO Mike Doustdar said on Monday as ‌many as 1.5 million patients in the U.S. may be using compounded versions of blockbuster GLP-1 drugs, underscoring how cheaper, ...

Novo Nordisk is chopping prices again for Wegovy, but doctors say the expense will remain challenging for patients without insurance. The drugmaker said Monday that it has started selling higher doses ...

Novo Nordisk will launch its oral Ozempic pill for type 2 diabetes in the U.S. next week, offering competitive pricing and ...

Novo Nordisk (NYSE: NVO) stock has been a trainwreck of late. In just the past 12 months, the Danish healthcare stock has lost around 60% of its value. Things have been going from bad to worse for the ...

The drugmaker is getting on the AI train in ways that could move the needle down the road.